NASDAQ:MACK

Merrimack Pharmaceuticals - MACK Stock Forecast, Price & News

$4.20

-0.14 (-3.23%)

(As of 08/11/2022 12:00 AM ET)

Add

Compare

Today's Range: $4.17
▼
$4.32
50-Day Range: $4.16
▼
$6.24
52-Week Range: $3.66
▼
$7.41

Volume: 9,083 shs
Average Volume: 59,054 shs
Market Capitalization: $56.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Merrimack Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.32% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.89
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$188,276 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

1012th out of 1,112 stocks

Pharmaceutical Preparations Industry

495th out of 544 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Merrimack Pharmaceuticals.

3.0

Short Interest

Percentage of Shares Shorted
2.32% of the float of Merrimack Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Merrimack Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
Change versus previous month
Short interest in Merrimack Pharmaceuticals has recently decreased by 1.85%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Merrimack Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Merrimack Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MACK.

3.3

News and Social Media Coverage

News Sentiment
Merrimack Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Merrimack Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for MACK on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Merrimack Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merrimack Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $188,276.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
25.80% of the stock of Merrimack Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
55.93% of the stock of Merrimack Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Merrimack Pharmaceuticals is -35.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merrimack Pharmaceuticals is -35.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Merrimack Pharmaceuticals has a P/B Ratio of 4.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Merrimack Pharmaceuticals (NASDAQ:MACK) Stock

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Merrimack Pharmaceuticals Trading Down 3.2 %

MACK Stock opened at $4.20 on Friday. The firm has a 50 day moving average of $5.41 and a 200-day moving average of $5.72. Merrimack Pharmaceuticals has a 12-month low of $3.66 and a 12-month high of $7.41. The company has a market cap of $56.32 million, a price-to-earnings ratio of -35.00 and a beta of 1.32.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Merrimack Pharmaceuticals in a report on Tuesday. They set a "sell" rating on the stock.

Insiders Place Their Bets

In related news, Director Noah G. Levy acquired 20,938 shares of the stock in a transaction dated Tuesday, June 14th. The stock was bought at an average cost of $5.17 per share, with a total value of $108,249.46. Following the purchase, the director now directly owns 1,010,515 shares of the company's stock, valued at $5,224,362.55. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last three months, insiders bought 35,478 shares of company stock valued at $188,276. Company insiders own 25.80% of the company's stock.

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

August 8, 2022 | seekingalpha.com

Merrimack Pharmaceuticals: Out For Now

August 4, 2022 | americanbankingnews.com

Merrimack Pharmaceuticals (NASDAQ:MACK) Earns Sell Rating from Analysts at StockNews.com

August 4, 2022 | marketwatch.com

Merrimack Pharma Shares Tumble Premarket After Ipsen's Onivyde Update >MACK

August 3, 2022 | nasdaq.com

Merrimack: Ipsen's Phase 3 Trial Of Onivyde Fails To Meet Primary Endpoint

August 3, 2022 | finance.yahoo.com

Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

July 24, 2022 | americanbankingnews.com

Merrimack Pharmaceuticals (NASDAQ:MACK) Research Coverage Started at StockNews.com

July 22, 2022 | nz.finance.yahoo.com

Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032: Visiongain Reports Ltd

July 19, 2022 | americanbankingnews.com

Corvus Pharmaceuticals (NASDAQ:CRVS) and Merrimack Pharmaceuticals (NASDAQ:MACK) Critical Survey

July 6, 2022 | finance.yahoo.com

Bullish insiders at Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) loaded up on US$574k of stock earlier this year

May 5, 2022 | seekingalpha.com

Merrimack Pharmaceuticals GAAP EPS of -$0.01

March 16, 2022 | bizjournals.com

This drug manufactured in Lynnwood can help you survive a nuclear blast

March 16, 2022 | bizjournals.com

This Mass. company’s drug can help you survive a nuclear blast

March 9, 2022 | finance.yahoo.com

Merrimack Reports Full Year 2021 Financial Results

March 9, 2022 | seekingalpha.com

Merrimack Pharmaceuticals reports FY results

January 27, 2022 | finance.yahoo.com

Insider Buying: The Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Co-Founder & Independent Director Just Bought 63% More Shares

January 24, 2022 | nasdaq.com

One Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insider upped their stake by 43% in the previous year

January 13, 2022 | nasdaq.com

Thursday 1/13 Insider Buying Report: MACK, ASO

January 5, 2022 | markets.businessinsider.com

Life Biosciences, Leading Developer of Therapeutics for Aging-Related Diseases, Completes $82 Million Series C Financing Round

December 6, 2021 | finance.yahoo.com

Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation

November 4, 2021 | finance.yahoo.com

Merrimack Reports Third Quarter 2021 Financial Results

October 7, 2021 | sg.finance.yahoo.com

Merrimack Pharmaceuticals, Inc. (MACK)

September 6, 2021 | finance.yahoo.com

A Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insider increased their holdings by 43% last year

August 5, 2021 | finance.yahoo.com

Merrimack Reports Second Quarter 2021 Financial Results

June 16, 2021 | uk.finance.yahoo.com

MACK Jun 2021 15.000 call

June 8, 2021 | finance.yahoo.com

Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Can Afford To Invest In Growth

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Company Calendar

Last Earnings: 5/10/2019
Today: 8/12/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:MACK
CUSIP: 59032810
CIK: 1274792
Web: www.merrimackpharma.com
Phone: 617-441-1000
Fax: 617-491-1386
Employees: 426
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,450,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -14.55%
Return on Assets: -13.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 31.85
Quick Ratio: 25.91

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.02 per share
Price / Book: 4.12

Miscellaneous

Outstanding Shares: 13,410,000
Free Float: 9,950,000
Market Cap: $56.32 million
Optionable: Optionable
Beta: 1.32

Key Executives

Mr. Gary L. Crocker M.B.A. (Age 70)
MBA, Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
Comp: $105.44k
Dr. Ulrik B. Nielsen Ph.D. (Age 50)
Co-Founder & Independent Director
Comp: $102.76k
Dr. Anthony J. Sinskey Ph.D. (Age 82)
Sc.D., Co-Founder and Scientific Advisor
Geoffrey Grande C.F.A.
Sr. Director of Communications
Ms. Ellen K. Forest (Age 58)
Head of HR
Dr. Fazal R. Khan Ph.D. (Age 72)
Sr. VP of Manufacturing
Dr. Daryl C. Drummond Ph.D. (Age 53)
Head of Research
Mr. Timothy R. Surgenor (Age 62)
Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MACK Stock - Frequently Asked Questions

How have MACK shares performed in 2022?: Merrimack Pharmaceuticals' stock was trading at $3.91 at the beginning of the year. Since then, MACK stock has increased by 7.4% and is now trading at $4.20.
View the best growth stocks for 2022 here.
When is Merrimack Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our MACK earnings forecast.
How were Merrimack Pharmaceuticals' earnings last quarter?: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.14.
When did Merrimack Pharmaceuticals' stock split?: Merrimack Pharmaceuticals shares reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Merrimack Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

What is Merrimack Pharmaceuticals' stock symbol?: Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
Who are Merrimack Pharmaceuticals' major shareholders?: Merrimack Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sepio Capital LP (2.36%), Yakira Capital Management Inc. (0.86%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen.
View institutional ownership trends.
How do I buy shares of Merrimack Pharmaceuticals?: Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Merrimack Pharmaceuticals' stock price today?: One share of MACK stock can currently be purchased for approximately $4.20.
How much money does Merrimack Pharmaceuticals make?: Merrimack Pharmaceuticals (NASDAQ:MACK) has a market capitalization of $56.32 million. The biopharmaceutical company earns $-2,450,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.
How many employees does Merrimack Pharmaceuticals have?: The company employs 426 workers across the globe.
How can I contact Merrimack Pharmaceuticals?: Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.merrimackpharma.com. The biopharmaceutical company can be reached via phone at 617-441-1000, via email at ir@merrimack.com, or via fax at 617-491-1386.

This page (NASDAQ:MACK) was last updated on 8/12/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Merrimack Pharmaceuticals - MACK Stock Forecast, Price & News

Merrimack Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Merrimack Pharmaceuticals (NASDAQ:MACK) Stock

Merrimack Pharmaceuticals Trading Down 3.2 %

Analyst Upgrades and Downgrades

Insiders Place Their Bets

MACK Stock News Headlines

MACK Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MACK Stock - Frequently Asked Questions

How have MACK shares performed in 2022?

When is Merrimack Pharmaceuticals' next earnings date?

How were Merrimack Pharmaceuticals' earnings last quarter?

When did Merrimack Pharmaceuticals' stock split?

What other stocks do shareholders of Merrimack Pharmaceuticals own?

What is Merrimack Pharmaceuticals' stock symbol?

Who are Merrimack Pharmaceuticals' major shareholders?

How do I buy shares of Merrimack Pharmaceuticals?

What is Merrimack Pharmaceuticals' stock price today?

How much money does Merrimack Pharmaceuticals make?

How many employees does Merrimack Pharmaceuticals have?

How can I contact Merrimack Pharmaceuticals?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™